Netoglitazone

Lenvatinib (E7080) is a multi-target inhibitor, mostly for VEGFR2(KDR)/VEGFR3(Flt-4) with IC50 of 4 nM/5.2 nM, less potent against VEGFR1/Flt-1, ~10-fold more selective for VEGFR2/3 against FGFR1, PDGFRα/β. Phase 3.Lenvatinib is an orally active

Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase

Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase

Linifanib (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR, CSF-1R, Flt-1/3 and PDGFRβ with IC50 of 4 nM, 3 nM, 3 nM/4 nM and 66 nM respectively, mostly effective in mutant kinase-dependent cancer cells (i.e. FLT3). Phase

a selective and potent p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively.

Contains 5 mg of the MEK inhibitor PD 98059 (Cat. No.

Application Metaraminol (+)-bitartrate salt has been used to study the effects of adrenergic agonists in the mouse model of endometriosis. Biochem/physiol Actions &#945:-adrenoceptor agonist.

Application Metaraminol (+)-bitartrate salt has been used to study the effects of adrenergic agonists in the mouse model of endometriosis. Biochem/physiol Actions &#945:-adrenoceptor agonist.

A cell-permeable isoxazoline compound that displays anti-inflammatory properties. Inhibits MIF dopachrome tautomerase activity by binding to its catalytic active site (IC 50 = 7 &#181M for D-dopachrome tautomerase) and suppresses the production of

Application Mitochondrial Fusion Promoter M1 has been used as a fusion promoter: to study its effects on peroxisome proliferator-activated receptor-&#947: coactivator (PGC)-1&#945: expression in breast cancer cells to study the link between

Biochem/physiol Actions MSDC-0160 is an mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is reported to enhance the

Biochem/physiol Actions MSDC-0160 is an mTOT (mitochondrial target of thiazolidinediones) modulator that targets the mitochondrial pyruvate carrier (MPC), which is a key controller of cellular metabolism. MSDC-0160 is reported to enhance the